This trial has completed recruitment on this platform, and is no longer accepting new referrals.
The mRNA-1345-P301 study is evaluating the safety and efficacy of an investigational vaccine, called mRNA-1345, to protect against RSV.
RSV can cause infections of the lungs and respiratory tract. Symptoms can be similar to a cold, and may include runny nose, sore throat, cough, and headache. However, RSV can lead to serious conditions like pneumonia especially for younger children and older adults. Currently there is not an approved vaccination for RSV.
Sites are located in the cities/states identified with the red pin:
The total length of participation in this clinical trial is approximately 2 years (25 months). It includes up to 8 trial visits and 26 brief communications (via telephone, email, or text message). You may have the option for some of the trial visits to be completed at home with a mobile health provider or through a video visit. Your trial doctor will discuss these options with you.
Participation in the mRNA-1345-P301 study lasts approximately two years and includes phone calls, telemedicine visits, and up to eight visits to the study site.
Insurance is not needed to join this clinical trial, and compensation for your time will be available.